|Articles|May 5, 2014

European Pharma Launches Strategy Manifesto

Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.

Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.

The manifesto is built on three “separate but highly interdependent pillars”:

1. Improve health outcomes & remove inequalities to better patient benefits;
2. Support sustainable & predictable healthcare systems to speed access to medicines;
3. Build a thriving innovative life sciences sector to promote European competitiveness. 

It follows the launch of EFPIA’s #HealthyEU Health and Growth campaign, which outlines opportunities and threats faced by the patients and the healthcare sector.

EFPIA President, Sanofi CEO Christopher Viehbacher, highlighted how the technological, behavioural and therapeutic innovations outlined in the Manifesto should be used to rebuild sustainable healthcare systems, improve access to medicines and “do a better job at preventing and treating chronic disease”.

The  research-based pharmaceutical industry employs over 700,000 people in Europe, and contributes  17% of total business enterprise R&D employment.

To view the EFPIA Maifesto, click here.


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.